Granite Point Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Granite Point Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000,000	Closed	-$141M	–	214
2020 Q4	$141M	Buy	1,000,000 +260,000	+35%	+$33.3M	7.22%	6
2020 Q3	$82.5M	Sell	740,000 -1,610,000	-69%	-$180M	4.47%	7
2020 Q2	$263M	Buy	+2,350,000	New	+$231M	13.4%	2
2020 Q1	–	Sell	-250,000	Closed	-$23.8M	–	105
2019 Q4	$23.8M	Buy	250,000 +100,000	+67%	+$8.65M	3.71%	7
2019 Q3	$11.4M	Sell	150,000 -375,000	-71%	-$31.2M	1.79%	7
2019 Q2	$46M	Buy	525,000 +25,000	+5%	+$2.13M	3.1%	10
2019 Q1	$45.3M	Buy	+500,000	New	+$42.5M	4.38%	7
2018 Q4	–	Sell	-500,000	Closed	-$47.9M	–	126
2018 Q3	$47.9M	Buy	500,000 +115,000	+30%	+$11.1M	3.18%	10
2018 Q2	$36.6M	Buy	+385,000	New	+$35.4M	3.28%	9

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Granite Point Capital Management's XBI Position: Q2 2023 in Review

Granite Point Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 3,000 shares — an estimated $229K sold.

Granite Point Capital Management first reported a position in XBI in Q2 2022 and held it in 4 quarters. The position peaked at $1.19M in Q3 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

Granite Point Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
Granite Point Capital Management sold 3,000 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $229K.
Granite Point Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 4 quarters.
Granite Point Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.19M in Q3 2022.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Granite Point Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.